

The ATM Registry

A clinical trials registry of all HIV/AIDS, Tuberculosis and Malaria trials conducted in sub-Saharan Africa

<u>Liesl Grobler¹</u>, Nandi Siegfried¹, Jimmy Volmink¹, Paul Garner², Karishma Busgeeth¹ and Vittoria Lutje²

- 1. South African Cochrane Centre, Medical Research Council, Cape Town, South Africa
- 2. Cochrane Infectious Disease Group, Liverpool School of Tropical Medicine, University of Liverpool, United Kingdom



Objectives



The ATM Registry aims to:

- Provide information on interventional research concerning the effects of preventive and treatment measures for HIV/AIDS, Tuberculosis and Malaria.
- 2. Enable researchers to identify research gaps that need to be addressed in future studies investigating these 3 diseases.
- Assist funders as well as those seeking funding by providing information on the scope, quality and funding patterns of trials conducted in Africa.
- 4. Keep all stakeholders, particularly those conducting systematic reviews of various health care interventions, informed of on-going trials, thus promoting the eventual inclusion of these trials into relevant systematic reviews.



Methods (1)



- Promote the prospective registration of all HIV/AIDS, Tuberculosis and Malaria trials conducted in sub-Saharan Africa
- Provide a repository, together with the necessary supporting systems and processes, for the prospective registration of all HIV/AIDS, Tuberculosis and Malaria trials conducted in sub-Saharan Africa




Methods (2)



- Conduct two pilot projects.
 - Project 1: prospective registration of all EDCTPfunded HIV/AIDS, Tuberculosis and Malaria trials conducted in sub-Saharan Africa.
 - Project 2: prospective registration of all trials investigating Artemisin-based combination treatments for malaria in sub-Saharan Africa.
- Collaborating with the WHO to ensure prerequisites for inclusion of ATM Registry into the International Clinical Trials Registry Platform (ICTRP) are met.
- Establish interactive web-based geographical information system (GIS) mapping of the ATM Registry in order to provide a 'bird's eye-view' of the entire dataset.



Results



- Established an Advisory group and a working group to advise on and execute the overall goals and objectives of the ATM Registry
- Determined the dataset to be captured from all prospectively registered trials
- Established a working relationship with the WHO International Clinical Trials Registry platform, ClinicalTrials.gov, Current Controlled Trials and Australian Clinical Trials Registry
- Established a working relationship with the South African National Clinical Trials Register
- Collected the minimum dataset of information on all EDCTP funded trials and all trials investigating Artemisinbased combination treatments for malaria conducted in sub-Saharan Africa.



Discussion & Conclusions



- A comprehensive registry of all HIV, TB and Malaria trials conducted in sub-Saharan Africa will contribute to EDCTP's goal to reduce poverty in developing countries by promoting access to clinical trial evidence on the effects of interventions, identifying gaps in clinical trial research and avoiding wasteful duplication of research.
- The success of this project depends on the establishment of sound relationships with various stakeholders and collaborators.
- We plan to extend our network into the rest of Africa and to other relevant stakeholders via the EDCTP network and the Southern African Development Community (SADEC) Health desk.



Future perspectives



- It is envisaged that the ATM registry will help to increase the coverage and quality of HIV, TB and malaria trials conducted in Africa.
- It should facilitate the eventual registration of all clinical trials conducted in Africa.
- Prospective registration of clinical trials is an important aspect in the drive to promote and enhance the use of evidence in health care decision making in Africa.
- The registry will facilitate the strengthening of networks between researchers and funders of clinical trials.
- The ATM Registry will facilitate clinical trial activity and capability in Africa by revealing the "clinical trials landscape" of the African continent to all relevant stakeholders.